Contributions
Abstract: EP1367
Type: ePoster
Abstract Category: Clinical aspects of MS - 7 MS symptoms
Aim: To validate and cross-culturally adapt both Croatian and Serbian versions of the Composite Autonomic Symptom Scale-31 (COMPASS-31) questionnaire for the detection of dysautonomia in multiple sclerosis (MS).
Methods: A total of 179 patients, 67 with clinically isolated syndrome (CIS) and 112 with MS at two MS centers (Zagreb and Belgrade) between April 1 and October 31, 2016 completed the COMPASS-31 questionnaire. Demographic and clinical data, including age, gender, MS phenotypes and the Expanded Disability Status Scale (EDSS) were collected. Internal consistency of the Serbian and Croatian versions of the COMPASS-31 was evaluated using Cronbach's alpha coefficient. Test-retest reliability of scores was evaluated by calculation of the intra-class correlation coefficient (ICC). Receiver operating characteristic (ROC) curve analysis was used to determine a cut-off value of COMPASS-31 total score.
Results: The Cronbach's alpha coefficient of total COMPASS-31 for the Croatian MS sample was 0.844 and for the Serbian MS sample 0.779. Joint analysis demonstrated range of Cronbach's alpha coefficients from 0.394 to 0.796, with values of four domains higher than 0.700. In both Croatian and Serbian samples, and in the total group, the Cronbach's alpha coefficient of COMPASS-31 was 0.785. Reproducibility measured by ICC was acceptable (0.795). With regard to the clinical validity, significant correlation (p< 0.001) was found between EDSS and the total COMPASS-31 score. Furthermore, significant differences between MS phenotypes were detected for Bladder and Gastrointestinal domains, and for the total COMPASS-31 score (p< 0.001, p=0.005, and p=0.027, respectively). Finally, significant differences between MS phenotypes in the proportion of participants with score >0, implicating the existence of at least one of the symptoms investigated in each domain, were detected for Secretomotor and Bladder domains (p=0.015 and p< 0.001, respectively). According to the ROC analysis, the highest sensitivity and specificity was detected for Orthostatic intolerance domain. The COMPASS-31 questionnaire sensitivity was 94.4% for MS patients who were experiencing orthostatic intolerance symptoms prior to testing; the specificity was 82.4%.
Conclusions: COMPASS-31 represents a valid and well accepted, self-assessment instrument for detection of dysautonomia in MS.
Disclosure:
Jelena Drulovic serves on scientific advisory boards for Bayer Schering Pharma, Merck Serono, Teva, Genzyme, a Sanofi Company, and received honoraria for speaking from Merck Serono, Teva, Bayer Schering, Genzyme, a Sanofi Company, Medis, Roche; and has also received research grant support from the Ministry of Education and Science, Republic of Serbia (project no. 175031).
Andjela Gavrilovic: nothing to disclose.
Luka Crnosija: nothing to disclose.
Darija Kisic-Tepavcevic has received research grant support from the Ministry of Education and Science, Republic of Serbia (projects no. 175031 and 175087).
Magdalena Krbot Skoric: nothing to disclose.
Jovana Ivanovic: nothing to disclose.
Ivan Adamec: nothing to disclose.
Irena Dujmovic serves on scientific advisory board for Bayer Schering Pharma, and received honoraria for speaking from Merck Serono, Roche and Medis; and has also received research grant support from the Ministry of Education and Science, Republic of Serbia (project no. 175031).
Anamari Junakovic: nothing to disclose.
Gorica Maric has received research grant support from the Ministry of Education and Science, Republic of Serbia (projects no. 175087 and 175090).
Vanja Martinovic has received research grant support from the Ministry of Education and Science, Republic of Serbia (project no. 175087).
Sarlota Mesaros serves on scientific advisory board for Merck Serono, and has received research grant support from the Ministry of Education and Science, Republic of Serbia (project no. 175031).
Tatjana Pekmezovic has received compensation for consulting services, travel expenses for scientific meetings, and speaking honoraria from Bayer Schering Pharma, Merck Serono, Actavis/Teva, Roche, Gedeon Richter, Novartis; supported by a grant of the Ministry of Education, Science and Technological Development, Republic of Serbia (No. 175087 and 175090).
Mario Habek participated as clinical investigator and/or speaker for: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals.
Abstract: EP1367
Type: ePoster
Abstract Category: Clinical aspects of MS - 7 MS symptoms
Aim: To validate and cross-culturally adapt both Croatian and Serbian versions of the Composite Autonomic Symptom Scale-31 (COMPASS-31) questionnaire for the detection of dysautonomia in multiple sclerosis (MS).
Methods: A total of 179 patients, 67 with clinically isolated syndrome (CIS) and 112 with MS at two MS centers (Zagreb and Belgrade) between April 1 and October 31, 2016 completed the COMPASS-31 questionnaire. Demographic and clinical data, including age, gender, MS phenotypes and the Expanded Disability Status Scale (EDSS) were collected. Internal consistency of the Serbian and Croatian versions of the COMPASS-31 was evaluated using Cronbach's alpha coefficient. Test-retest reliability of scores was evaluated by calculation of the intra-class correlation coefficient (ICC). Receiver operating characteristic (ROC) curve analysis was used to determine a cut-off value of COMPASS-31 total score.
Results: The Cronbach's alpha coefficient of total COMPASS-31 for the Croatian MS sample was 0.844 and for the Serbian MS sample 0.779. Joint analysis demonstrated range of Cronbach's alpha coefficients from 0.394 to 0.796, with values of four domains higher than 0.700. In both Croatian and Serbian samples, and in the total group, the Cronbach's alpha coefficient of COMPASS-31 was 0.785. Reproducibility measured by ICC was acceptable (0.795). With regard to the clinical validity, significant correlation (p< 0.001) was found between EDSS and the total COMPASS-31 score. Furthermore, significant differences between MS phenotypes were detected for Bladder and Gastrointestinal domains, and for the total COMPASS-31 score (p< 0.001, p=0.005, and p=0.027, respectively). Finally, significant differences between MS phenotypes in the proportion of participants with score >0, implicating the existence of at least one of the symptoms investigated in each domain, were detected for Secretomotor and Bladder domains (p=0.015 and p< 0.001, respectively). According to the ROC analysis, the highest sensitivity and specificity was detected for Orthostatic intolerance domain. The COMPASS-31 questionnaire sensitivity was 94.4% for MS patients who were experiencing orthostatic intolerance symptoms prior to testing; the specificity was 82.4%.
Conclusions: COMPASS-31 represents a valid and well accepted, self-assessment instrument for detection of dysautonomia in MS.
Disclosure:
Jelena Drulovic serves on scientific advisory boards for Bayer Schering Pharma, Merck Serono, Teva, Genzyme, a Sanofi Company, and received honoraria for speaking from Merck Serono, Teva, Bayer Schering, Genzyme, a Sanofi Company, Medis, Roche; and has also received research grant support from the Ministry of Education and Science, Republic of Serbia (project no. 175031).
Andjela Gavrilovic: nothing to disclose.
Luka Crnosija: nothing to disclose.
Darija Kisic-Tepavcevic has received research grant support from the Ministry of Education and Science, Republic of Serbia (projects no. 175031 and 175087).
Magdalena Krbot Skoric: nothing to disclose.
Jovana Ivanovic: nothing to disclose.
Ivan Adamec: nothing to disclose.
Irena Dujmovic serves on scientific advisory board for Bayer Schering Pharma, and received honoraria for speaking from Merck Serono, Roche and Medis; and has also received research grant support from the Ministry of Education and Science, Republic of Serbia (project no. 175031).
Anamari Junakovic: nothing to disclose.
Gorica Maric has received research grant support from the Ministry of Education and Science, Republic of Serbia (projects no. 175087 and 175090).
Vanja Martinovic has received research grant support from the Ministry of Education and Science, Republic of Serbia (project no. 175087).
Sarlota Mesaros serves on scientific advisory board for Merck Serono, and has received research grant support from the Ministry of Education and Science, Republic of Serbia (project no. 175031).
Tatjana Pekmezovic has received compensation for consulting services, travel expenses for scientific meetings, and speaking honoraria from Bayer Schering Pharma, Merck Serono, Actavis/Teva, Roche, Gedeon Richter, Novartis; supported by a grant of the Ministry of Education, Science and Technological Development, Republic of Serbia (No. 175087 and 175090).
Mario Habek participated as clinical investigator and/or speaker for: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals.